Pruritus is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pruritus have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pruritus compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pruritus overview
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin, and reactions to drugs. Symptoms include redness, bumps, spots or blisters, dry, cracked skin, and leathery or scaly texture to the skin. Risk factors include heat, allergies, asthma, hay fever, hives, and eczema. Treatment includes corticosteroids, antihistamines, and antidepressants.
For a complete picture of PTSR and LoA scores for drugs in Pruritus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.